ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Takeda, Grifols and Octapharma side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Takeda×Grifols×Octapharma×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

TakedaGrifolsOctapharma
studies on the registry1,75410871
open to participants now8688
phase 3 studies under way4466
reach primary completion within a year4715
programswith a study of their own in two years2551

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseTakedaGrifolsOctapharma
Phase 1

Takeda: 1 of its 25 programs at phase 1

  1. TAK-781phase 1
4%

Grifols: 1 of its 5 programs at phase 1

  1. GIGA-2339phase 1
20%
00%
Phase 2

Takeda: 5 of its 25 programs at phase 2

  1. rusfertidephase 2
  2. Anti-CCR8 Antibody-drug Conjugate TAK-188phase 2
  3. Anti-PD-L1/Anti-Vd1 T-cell Engager TAK-505phase 2
  4. TAK-411phase 2
  5. TAK-951phase 2
20%

Grifols: 1 of its 5 programs at phase 2

  1. GRF312phase 2
20%
00%
Phase 3

Takeda: 11 of its 25 programs at phase 3

  1. zasocitinibphase 3
  2. elriterceptphase 3
  3. mezagitamabphase 3
  4. TAK-360phase 3
  5. TAK-003phase 3

and 6 more — sign in to see them all

44%

Grifols: 2 of its 5 programs at phase 3

  1. Immune Globulin Subcutaneous Humanphase 3
  2. Alpha-1 15%phase 3
40%
00%
Approved, new studies

Takeda: 8 of its 25 programs at approved, new studies

  1. Immunoglobulins, Intravenousapproved, new study
  2. Brentuximab Vedotinapproved, new study
  3. Vinblastineapproved, new study
  4. Vortioxetineapproved, new study
  5. antihemophilic factor, human recombinantapproved, new study

and 3 more — sign in to see them all

32%

Grifols: 1 of its 5 programs at approved, new studies

  1. Immunoglobulins, Intravenousapproved, new study
20%

Octapharma: 1 of its 1 programs at approved, new studies

  1. Panzygaapproved, new study
100%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Takeda7 readouts · 4 phase 3

Takeda, Nov ’26: 1 program whose next study reaches primary completion

  1. TAK-360phase 3 · Nov 30 · NCT06952699

Takeda, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. oveporextonphase 3 · Dec 17 · NCT07363720
·

Takeda, Feb ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zasocitinibphase 3 · Feb 5 · NCT07244263
  2. teduglutidephase 3 · Feb 10 · NCT06973304

Takeda, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. apadamtase alfaphase 3 · Mar 16 · NCT04683003

Takeda, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. TAK-003phase 3 · Apr 14 · NCT06579755
·····

Takeda, Oct ’27: 1 program whose next study reaches primary completion

  1. rusfertidephase 2 · Oct 28 · NCT07648030
Grifols1 readouts · 1 phase 3··········

Grifols, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Alpha-1 15%phase 3 · Sep 30 · NCT07555483
·
Octapharma0 readouts · 0 phase 3············
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 20, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Takeda

New programs 1

  • TAK-664approved, new study · first study · Aug 26 · Primary Immunodeficiency Diseases

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 3

Grifols

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Octapharma

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 6 in all. A program counts in each condition its studies name most.

ConditionTakedaGrifolsOctapharma
Purpura, Thrombocytopenic, Idiopathicall three · compare here

Takeda in Purpura, Thrombocytopenic, Idiopathic: 2 programs

  1. mezagitamabphase 3
  2. Immunoglobulins, Intravenousapproved, new study

Their studies: Takeda’s studies of Purpura, Thrombocytopenic, Idiopathic in search

Grifols in Purpura, Thrombocytopenic, Idiopathic: 1 program

  1. Immunoglobulins, Intravenousapproved, new study

Their studies: Grifols’ studies of Purpura, Thrombocytopenic, Idiopathic in search

Octapharma in Purpura, Thrombocytopenic, Idiopathic: 1 program

  1. Panzygaapproved, new study

Their studies: Octapharma’s studies of Purpura, Thrombocytopenic, Idiopathic in search

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating2 of 3 · compare here

Takeda in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: 4 programs

  1. TAK-411phase 2
  2. Immunoglobulins, Intravenousapproved, new study
  3. Hyaluronoglucosaminidaseapproved, new study
  4. Immunoglobulin Gapproved, new study

Their studies: Takeda’s studies of Polyradiculoneuropathy, Chronic Inflammatory Demyelinating in search

Grifols in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: 2 programs

  1. Immune Globulin Subcutaneous Humanphase 3
  2. Immunoglobulins, Intravenousapproved, new study

Their studies: Grifols’ studies of Polyradiculoneuropathy, Chronic Inflammatory Demyelinating in search

–
Primary Immunodeficiency Diseases2 of 3 · compare here

Takeda in Primary Immunodeficiency Diseases: 4 programs

  1. Immunoglobulins, Intravenousapproved, new study
  2. TAK-664approved, new study
  3. Hyaluronoglucosaminidaseapproved, new study
  4. Immunoglobulin Gapproved, new study

Their studies: Takeda’s studies of Primary Immunodeficiency Diseases in search

Grifols in Primary Immunodeficiency Diseases: 1 program

  1. Immunoglobulins, Intravenousapproved, new study

Their studies: Grifols’ studies of Primary Immunodeficiency Diseases in search

–
Agammaglobulinemia2 of 3 · compare here–

Grifols in Agammaglobulinemia: 1 program

  1. Immune Globulin Subcutaneous Humanphase 3

Their studies: Grifols’ studies of Agammaglobulinemia in search

Octapharma in Agammaglobulinemia: 1 program

  1. Panzygaapproved, new study

Their studies: Octapharma’s studies of Agammaglobulinemia in search

Immunologic Deficiency Syndromes2 of 3 · compare here

Takeda in Immunologic Deficiency Syndromes: 1 program

  1. Immunoglobulins, Intravenousapproved, new study

Their studies: Takeda’s studies of Immunologic Deficiency Syndromes in search

Grifols in Immunologic Deficiency Syndromes: 1 program

  1. Immunoglobulins, Intravenousapproved, new study

Their studies: Grifols’ studies of Immunologic Deficiency Syndromes in search

–
Myasthenia Gravis2 of 3 · compare here

Takeda in Myasthenia Gravis: 1 program

  1. Immunoglobulins, Intravenousapproved, new study

Their studies: Takeda’s studies of Myasthenia Gravis in search

Grifols in Myasthenia Gravis: 1 program

  1. Immunoglobulins, Intravenousapproved, new study

Their studies: Grifols’ studies of Myasthenia Gravis in search

–

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Takeda 12 of 25 · Grifols 0 of 5 · Octapharma 0 of 1 programs (12 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.